Lactobacillus rhamnosus GG für Irritable Bowel Syndrome (IBS)
B Evidenz Mindestens eine randomisierte Studie unterstützt dies, mit überwiegend konsistenten Ergebnissen.Several RCTs show improvement in IBS symptoms, particularly bloating and abdominal pain. Effect strongest in IBS-D subtype. Results not uniform across all IBS subtypes.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dlactobacillus\u002Drhamnosus\u002Dgg\u0026condition\u003Dibs';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
B
Fazit
Several RCTs show improvement in IBS symptoms, particularly bloating and abdominal pain. Effect strongest in IBS-D subtype. Results not uniform across all IBS subtypes.
Key Study Findings
Meta-Analysis
Strain-Specific Systematic Review with Meta-Analysis of Probiotics Efficacy in the Treatment of Irritable Bowel Syndrome.
Dose: None
vs.: placebo
Outcome: improvement in key IBS symptoms
Wirkung: None
None
Population: patients with IBS from 32 RCTs evaluating 10 probiotic strains
Randomized Controlled Trial
3 weeks
Double-blind
Nutraceuticals and Pain Disorders of the Gut-Brain Interaction in Infants and Children: A Narrative Review …
Dose: None
vs.: Placebo
Outcome: Pain outcomes
Wirkung: None
None
Population: IBS patients
Systematic Review
n=3
Effectiveness of Probiotics in Children With Functional Abdominal Pain Disorders and Functional Constipation: A Systematic …
Dose: None
vs.: None
Outcome: Abdominal pain frequency/intensity, constipation
Wirkung: None
None
Population: Children with FAPD or functional constipation
Systematic Review
Probiotics for Irritable Bowel Syndrome: Clinical Data in Children.
Dose: various probiotic strains
vs.: placebo
Outcome: IBS symptom improvement in children
Wirkung: LGG showed benefit in some studies
None
Population: Children with IBS
Review
Probiotic Bacterial and Fungal Strains: Claims with Evidence.
Dose: None
vs.: None
Outcome: None
Wirkung: None
None
Population: Various populations (probiotic claims review)
Review
Bugs and Guts: Practical Applications of Probiotics for Gastrointestinal Disorders in Children.
Dose: None
vs.: None
Outcome: None
Wirkung: None
None
Population: IBD patients
Key Statistics
8
Studien
1200
Teilnehmer
↑
Positive
B
Bewertung
Referenced Papers
Journal of clinical …
2026
Nutrients
2024
5 Zitierungen
Effectiveness of Probiotics in Children With Functional Abdominal Pain Disorders and Functional Constipation: A Systematic Review.
Systematic Review
Journal of clinical …
2018
34 Zitierungen
Digestive diseases (Basel, …
2016
37 Zitierungen
Probiotics for Irritable Bowel Syndrome: Clinical Data in Children.
Systematic Review
Journal of pediatric …
2016
19 Zitierungen
The use of probiotics in pediatric gastroenterology: a review of the literature and recommendations by Latin-American experts.
Systematic Review
Paediatric drugs
2015
122 Zitierungen
Bugs and Guts: Practical Applications of Probiotics for Gastrointestinal Disorders in Children.
Review
Nutrition in clinical …
2015
31 Zitierungen
BMC gastroenterology
2010
91 Zitierungen
Alimentary pharmacology & …
2007
102 Zitierungen
Asia Pacific journal …
2006
45 Zitierungen
Asia Pacific journal …
2006
Alimentary pharmacology & …
2005
398 Zitierungen
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
Übliche Dosierungen
- general:
- 10-20 billion CFU/day
- ibssupport:
- 10 billion CFU/day for 4-8 weeks
- aadprevention:
- 10-20 billion CFU/day (start with antibiotic, continue 7 days after)
Obergrenze: Generally well-tolerated up to 40 billion CFU/day in clinical trials
In der Forschung untersuchte Dosierungen
| Dosierung | Dauer | Wirkung | N |
|---|---|---|---|
| None | -- | Positive | -- |
| None | 3 weeks | Positive | -- |
| None | -- | Mixed | 3 |
| various probiotic strains | -- | Mixed | -- |
| None | -- | Mixed | -- |
| None | -- | Mixed | -- |
| None | -- | Mixed | -- |
| None | 26.0 weeks | Mixed | -- |
Beste Einnahmezeit: On an empty stomach or 30 minutes before meals for optimal survival
Safety & Side Effects
Gemeldete Nebenwirkungen
- ⚠ Mild gas and bloating during initial use (usually resolves in 1-2 weeks)
- ⚠ Rare reports of bacteremia in severely immunocompromised individuals
- ⚠ Occasional loose stools during adjustment period
- ⚠ Very rare: systemic infection in critically ill patients with central venous catheters
Bekannte Wechselwirkungen
- ● Antibiotics (may reduce probiotic viability; space dosing 2 hours apart)
- ● Immunosuppressants (theoretical risk of infection in immunocompromised patients)
- ● Antifungals (no known interaction but may affect gut flora balance)
Tolerierbare Höchstaufnahmemenge: Generally well-tolerated up to 40 billion CFU/day in clinical trials
Konsultieren Sie immer Ihren Arzt, bevor Sie ein Nahrungsergänzungsmittel einnehmen.Konsultieren Sie immer Ihren Arzt, bevor Sie ein Nahrungsergänzungsmittel einnehmen.
Frequently Asked Questions
Does Lactobacillus rhamnosus GG help with Irritable Bowel Syndrome (IBS)?
Based on 8 studies with 1,200 participants, there is moderate evidence from clinical studies that Lactobacillus rhamnosus GG may support Irritable Bowel Syndrome (IBS) management. Our evidence grade is B (Good Evidence).
How much Lactobacillus rhamnosus GG should I take for Irritable Bowel Syndrome (IBS)?
Studies have used various dosages. A commonly studied range is 10-20 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Lactobacillus rhamnosus GG?
Reported side effects may include Mild gas and bloating during initial use (usually resolves in 1-2 weeks), Rare reports of bacteremia in severely immunocompromised individuals, Occasional loose stools during adjustment period, Very rare: systemic infection in critically ill patients with central venous catheters. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Lactobacillus rhamnosus GG and Irritable Bowel Syndrome (IBS)?
We rate the evidence as Grade B (Good Evidence). This rating is based on 8 peer-reviewed studies with 1,200 total participants. The overall direction of effect is positive.
Related Evidence
Andere Inhaltsstoffe für Irritable Bowel Syndrome (IBS)
Lactobacillus rhamnosus GG für andere Beschwerden
References
- [1] Roman Maslennikov et al.. J Clin Med. 2026. Strain-Specific Systematic Review with Meta-Analysis of Probiotics Efficacy in the Treatment of Irritable Bowel Syndrome. doi:10.3390/jcm15031152 PubMed
- [2] Silvia Salvatore et al.. Nutrients. 2024. Nutraceuticals and Pain Disorders of the Gut-Brain Interaction in Infants and Children: A Narrative Review and Practical Insights. doi:10.3390/nu16030349 PubMed
- [3] Carrie A M Wegh et al.. J Clin Gastroenterol. 2018. Effectiveness of Probiotics in Children With Functional Abdominal Pain Disorders and Functional Constipation: A Systematic Review. doi:10.1097/MCG.0000000000001054 PubMed
- [4] Hania Szajewska et al.. Dig Dis. 2016. Probiotic Bacterial and Fungal Strains: Claims with Evidence. doi:10.1159/000443359 PubMed
- [5] Eleonora Giannetti et al.. J Pediatr Gastroenterol Nutr. 2016. Probiotics for Irritable Bowel Syndrome: Clinical Data in Children. doi:10.1097/MPG.0000000000001220 PubMed
- [6] Sylvia Cruchet et al.. Paediatr Drugs. 2015. The use of probiotics in pediatric gastroenterology: a review of the literature and recommendations by Latin-American experts. doi:10.1007/s40272-015-0124-6 PubMed
- [7] Danielle Barnes et al.. Nutr Clin Pract. 2015. Bugs and Guts: Practical Applications of Probiotics for Gastrointestinal Disorders in Children. doi:10.1177/0884533615610081 PubMed
- [8] Anna Lyra et al.. BMC Gastroenterol. 2010. Effect of a multispecies probiotic supplement on quantity of irritable bowel syndrome-related intestinal microbial phylotypes. doi:10.1186/1471-230X-10-110 PubMed
- [9] K Kajander et al.. Aliment Pharmacol Ther. 2007. Effects of multispecies probiotic supplementation on intestinal microbiota in irritable bowel syndrome. doi:10.1111/j.1365-2036.2007.03391.x PubMed
- [10] Seppo Salminen et al.. Asia Pac J Clin Nutr. 2006. Intestinal colonisation, microbiota and future probiotics? PubMed
- [11] Kajsa Kajander et al.. Asia Pac J Clin Nutr. 2006. Clinical studies on alleviating the symptoms of irritable bowel syndrome. PubMed
- [12] K Kajander et al.. Aliment Pharmacol Ther. 2005. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. doi:10.1111/j.1365-2036.2005.02579.x PubMed
FDA-Haftungsausschluss: Diese Aussagen wurden nicht von der Food and Drug Administration bewertet. Die Produkte und Informationen auf dieser Website sind nicht dazu bestimmt, Krankheiten zu diagnostizieren, zu behandeln, zu heilen oder zu verhindern. Die dargestellten Evidenzbewertungen basieren auf unserer Analyse veröffentlichter begutachteter Forschung und stellen keine medizinische Beratung dar. Konsultieren Sie immer Ihren Arzt, bevor Sie mit der Einnahme von Nahrungsergänzungsmitteln beginnen.